PACB vs BBNX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PACB · Pacific Biosciences of California$2.26 ▼ 7.20%
BBNX · Beta Bionics$15.70 ▲ 1.36%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PACB +28.4%
- BBNX -42.9%
Head to head
| Metric | PACB | BBNX |
|---|---|---|
| Price | $2.26 | $15.70 |
| Change today | ▼ 7.20% | ▲ 1.36% |
| Market cap | $705.65M | $853.56M |
| Return, 3 months | +96.1% | -4.3% |
| Return, year to date | +20.6% | -48.5% |
| Return, 1 year | +28.1% | -40.3% |
| P/E (TTM) | -5.4 | -10.3 |
| P/B | -11.5 | 2.1 |
| P/E percentile vs own 5y | 37th | 45th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -1.9% | +30.3% |
| Net profit growth (YoY) | -6.7% | -71.4% |
| Gross margin | 36.4% | 58.6% |
| Operating margin | -102.6% | -72.7% |
| Net margin | -82.5% | -65.3% |
| Return on equity | -929.3% | -23.9% |
| Analyst target vs. price | -2.9% | +61.5% |
| Analyst buy share | 60% | 75% |
| RSI (14) | 50 | 41 |
| 30-day volatility | 142.2% | 87.4% |
| Max drawdown, 1 year | -58.4% | -72.3% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BBNX is the largest of the group by market value.
- PACB has returned the most over the past year.
- BBNX carries the lowest trailing P/E.
- BBNX is growing revenue fastest.
- BBNX keeps the most profit per dollar of sales.
- BBNX has been the calmest stock over the last 30 days.